NCT04716634View on ClinicalTrials.gov

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

February 22, 2024

Study Completion Date

February 22, 2024

Conditions
Advanced Solid Tumors
Interventions
DRUG

Tislelizumab

Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.

DRUG

Fruquintinib

Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)

Trial Locations (13)

10408

National Cancer Center, Goyang-si

13620

Seoul National University Bundang Hospital, Seongnam-si

150000

Harbin Medical University Cancer Hospital, Harbin

250117

Shandong Cancer Hospital, Jinan

252000

Liaocheng Peoples Hospital, Liaocheng

276001

Linyi Cancer Hospital, Linyi

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310016

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

350014

Fujian Cancer Hospital, Fuzhou

450000

Henan Cancer Hospital, Zhengzhou

610041

West China Hospital, Sichuan University, Chengdu

730000

The First Hospital of Lanzhou University, Lanzhou

05505

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
collaborator

Hutchison Medipharma Limited

INDUSTRY

lead

BeiGene

INDUSTRY

NCT04716634 - Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors | Biotech Hunter | Biotech Hunter